Register for a Clinical Trial

Protocol GA28950
Title EFFICACY AND SAFETY OF ETROLIZUMAB DURING INDUCTION AND MAINTENANCE IN PATIENTS WITH MODERATE TOSEVERE ACTIVE ULCERATIVE COLITIS WHO ARE REFRACTORY TO OR INTOLERANT OF TNF INHIBITORS
Phase III
Area Ulcerative Colitis
Indication

Active Severe to Moderate Ulcerative Colitis

Treatment

ETROLIZUMAB

Requirement

Intolerant or Refractory to: Infliximab (Remicade), Adalimumab (Humira), or Golimumab(Simponi)

Trial:
Your First Name:
Your Last Name:
Phone Number:
Address:
City:
State:
ZIP Code:
E-mail Address:
Cancel